Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design

Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Gavin Dabrera, Mary Ramsay, Jamie Lopez Bernal
doi: https://doi.org/10.1101/2023.09.28.23296290

Article usage

Article usage: September 2023 to May 2026

AbstractFullPdf
Sep 2023157018
Oct 2023128376601
Nov 202341223157
Dec 2023190760
Jan 2024204769
Feb 2024189933
Mar 20241611836
Apr 20241361617
May 202493414
Jun 202461223
Jul 202441518
Aug 20243926
Sep 2024661310
Oct 202444917
Nov 20244617
Dec 202452111
Jan 202572139
Feb 202549369
Mar 20252625114
Apr 20253041628
May 20251133118
Jun 2025542428
Jul 2025452632
Aug 2025765338
Sep 2025703047
Oct 2025492226
Nov 2025592730
Dec 2025591830
Jan 2026918026
Feb 20264515022
Mar 2026617033
Apr 2026345724
May 2026676144
Back to top
Posted September 29, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design
Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Gavin Dabrera, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2023.09.28.23296290; doi: https://doi.org/10.1101/2023.09.28.23296290
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area